Axsome Therapeutics, Inc..
AXSM.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies for central nervous system (CNS) disorders. The company's pipeline includes product candidates for the treatment of depression, Alzheimer's disease agitation, migraine, and other CNS conditions. Axsome's p...Show More
Better Health for All
-40
Axsome Therapeutics' entire business is devoted to developing novel therapies for central nervous system (CNS) disorders, including FDA-approved treatments for major depressive disorder, narcolepsy, sleep apnea, and migraine, indicating a portfolio focused on health improvement.
1
The company has no revenue from products with significant negative health impacts. However, its product Auvelity carries a Boxed Warning for suicidal thoughts and behaviors,
2
and common adverse reactions include dizziness (16%), headache (8%), and diarrhea (7%).
3
The company reported zero OSHA-reportable employee injuries in 2023
4
and has not recalled any products.
5
Axsome operates patient assistance programs providing free drug to qualifying patients
6
and co-pay programs allowing eligible patients to pay as little as $10 for a 30- or 90-day prescription,
7
though a savings card program expired in 2022.
8
The company discloses transfers of value to healthcare providers through CMS’s Open Payments portal.
9
Axsome's intellectual property portfolio for AXS-05 extends to at least 2034-43,
10
and a patent settlement with Teva Pharmaceuticals allows generic Auvelity entry no earlier than 2038 or 2039.
11
The company seeks to minimize greenhouse gas impact from product development and manufacturing.
12
Axsome provides a comprehensive employee wellness program, including mental health support,
13
and offers two mental health days annually.
14
The company conducts mandatory healthcare compliance training for sales personnel.
15
Auvelity is contraindicated in patients undergoing abrupt discontinuation of alcohol.
16
Axsome is committed to conducting robust and transparent clinical trials,
17
protecting human rights, and ensuring informed consent and patient privacy.
18
Fair Money & Economic Opportunity
0
Axsome Therapeutics, Inc. is a biopharmaceutical company, and the provided article details information about a prescription medication.
1
The company's core business and the content of the article do not relate to financial services such as lending, insurance, or deposit services, which are the focus of the 'Fair Money & Economic Opportunity' value. As no article provides specific, concrete data points for any of the KPIs related to financial products or services, all KPIs are omitted.
2
Fair Pay & Worker Respect
0
In 2024, the CEO pay ratio was 21:1, with the CEO receiving $10,364,688 in total compensation and the median employee pay being $487,562.
1
As of July 29, 2024, none of the company's 589 full-time employees were represented by a collective bargaining agreement.
2
Employee engagement, based on Glassdoor reviews, was rated 3.2 out of 5 stars as of February 2026.
3
The company provides a robust employment package that includes healthcare and insurance benefits, health savings and flexible spending accounts, paid time off, and family leave, indicating 100% health insurance coverage for employees.
4
Fair Trade & Ethical Sourcing
0
Axsome Therapeutics is a biopharmaceutical company focused on developing therapies for CNS disorders. Given the nature of its business, which primarily involves research, development, and manufacturing of highly regulated pharmaceutical products, the company does not procure or trade physical commodities typically associated with fair-trade certifications or high-risk materials like conflict minerals or uncertified palm oil. Therefore, the KPIs for 'fair_trade_cert_share' and 'materials_risk_index' are assessed as N/A.
1
No other specific, concrete data points regarding Axsome Therapeutics' fair trade or ethical sourcing practices, such as audit frequency, forced/child labor incidents, traceability coverage, remediation speed, ethical clause coverage, or supplier diversity spend, are provided in the available articles.
2
Honest & Fair Business
50
Sustainalytics reports the company's Controversy Level as 'None', indicating an absence of recorded controversies.
1
Kind to Animals
0
No evidence available to assess Axsome Therapeutics, Inc. on Kind to Animals.
No War, No Weapons
0
No evidence available to assess Axsome Therapeutics, Inc. on No War, No Weapons.
Planet-Friendly Business
-20
Approximately 30% of the company's electricity is sourced from renewable energy.
1
The company has not been engaged in any legal proceedings relating to alleged non-compliance with environmental laws.
2
Additionally, none of its operations are located within water-stressed areas.
3
Respect for Cultures & Communities
10
Axsome Therapeutics has no reported cultural appropriation incidents.
1
The company's operations, focused on biopharmaceutical R&D and clinical trials, do not appear to impact cultural contexts or require free, prior, and informed consent processes,
2
nor do they necessitate specific community representation on governance bodies. Axsome is endorsing NAMI’s Compartiendo Esperanza, a Spanish-language initiative that provides culturally relevant support and resources for Latino communities.
3
Safe & Smart Tech
-40
Axsome Therapeutics states compliance with major regulations including CCPA, CPRA, FDA, OIG, and ICH guidelines.
1
However, a shareholder investigation alleges deficiencies in manufacturing processes and potential securities law violations, indicating some compliance gaps.
2
Users have moderate data control options, including managing targeted advertising/cookie preferences, opting out of marketing communications, and requesting data deletion, but the services are not designed for children under 18, and information from known minors will be deleted.
3
The company mentions access controls as a technical safeguard and allows login via Google or Apple accounts, which is an industry-standard approach.
4
Axsome regularly assesses and tests its cybersecurity policies, standards, processes, and practices, including vulnerability assessments, threat modeling, and penetration testing, with critical vulnerabilities patched within 21-30 days on average.
5
Security testing is regular for some systems, including audits and tabletop exercises.
6
The company retains personal information only as reasonably necessary for stated purposes or as disclosed at the time of collection, aligning with good data minimization practices.
7
The company provides regular training for personnel regarding cybersecurity threats, which is an industry-standard approach, but specific completion rates or effectiveness metrics are not provided.
8
Zero Waste & Sustainable Products
-40
Axsome Therapeutics utilizes green packaging solutions for 62% of its product lines.
1
The company has a waste reduction target of 8.6%.
2
It has implemented several waste reduction initiatives, including providing segregated on-site disposal and recycling containers, procuring eco-conscious and compostable or reusable kitchen and office supplies, using dispensers to reduce packaging waste, and offering reusable mugs to new employees.
3
Axsome encourages its suppliers to minimize waste, and 75% of its suppliers are assessed for environmental compliance.
4